167 related articles for article (PubMed ID: 33563181)
1. Induced Fit Docking and Automated QSAR Studies Reveal the ER-α Inhibitory Activity of Cannabis sativa in Breast Cancer.
Kikiowo B; Ogunleye AJ; Iwaloye O; Ijatuyi TT; Adelakun NS; Alashe WO
Recent Pat Anticancer Drug Discov; 2021; 16(2):273-284. PubMed ID: 33563181
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
[TBL] [Abstract][Full Text] [Related]
3. A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance.
Ma Y; Preet A; Tomita Y; De Oliveira E; Zhang L; Ueda Y; Clarke R; Brown M; Rosen EM
Oncotarget; 2015 Dec; 6(38):40388-404. PubMed ID: 26575173
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, and
Choudhari RC; Kaur K; Das A; Jaitak V
Curr Comput Aided Drug Des; 2024; 20(5):640-652. PubMed ID: 37888813
[TBL] [Abstract][Full Text] [Related]
5. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
[TBL] [Abstract][Full Text] [Related]
6. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
[TBL] [Abstract][Full Text] [Related]
7. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.
Wardell SE; Nelson ER; Chao CA; McDonnell DP
Clin Cancer Res; 2013 May; 19(9):2420-31. PubMed ID: 23536434
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and
Lavanya KJ; Kaur K; Jaitak V
Curr Comput Aided Drug Des; 2024; 20(4):374-383. PubMed ID: 36944620
[TBL] [Abstract][Full Text] [Related]
9. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
[TBL] [Abstract][Full Text] [Related]
10. Development of leads targeting ER-α in breast cancer: An in silico exploration from natural domain.
Ashtekar SS; Bhatia NM; Bhatia MS
Steroids; 2018 Mar; 131():14-22. PubMed ID: 29307843
[TBL] [Abstract][Full Text] [Related]
11.
Laskar YB; Mazumder PB; Talukdar AD
J Biomol Struct Dyn; 2023 Feb; 41(2):611-633. PubMed ID: 34854367
[TBL] [Abstract][Full Text] [Related]
12. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
[TBL] [Abstract][Full Text] [Related]
13. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
Girault I; Bièche I; Lidereau R
Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
[TBL] [Abstract][Full Text] [Related]
14. HEXIM1 is a critical determinant of the response to tamoxifen.
Ketchart W; Ogba N; Kresak A; Albert JM; Pink JJ; Montano MM
Oncogene; 2011 Aug; 30(33):3563-9. PubMed ID: 21423213
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators.
Shoda T; Kato M; Harada R; Fujisato T; Okuhira K; Demizu Y; Inoue H; Naito M; Kurihara M
Bioorg Med Chem; 2015 Jul; 23(13):3091-6. PubMed ID: 26003343
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells.
Yu HN; Noh EM; Lee YR; Roh SG; Song EK; Han MK; Lee YC; Shim IK; Lee SJ; Jung SH; Kim JS; Youn HJ
Biochem Biophys Res Commun; 2008 Dec; 377(1):242-7. PubMed ID: 18835379
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.
Ma Y; Tomita Y; Preet A; Clarke R; Englund E; Grindrod S; Nathan S; De Oliveira E; Brown ML; Rosen EM
Mol Endocrinol; 2014 Dec; 28(12):1971-86. PubMed ID: 25264941
[TBL] [Abstract][Full Text] [Related]
18. Multitargeted Molecular Docking Study of Natural-Derived Alkaloids on Breast Cancer Pathway Components.
Singla R; Jaitak V
Curr Comput Aided Drug Des; 2017 Nov; 13(4):294-302. PubMed ID: 28382865
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial anti-proliferative effects of tamoxifen and naringenin: The role of four estrogen receptor subtypes.
Xu Z; Huang B; Liu J; Wu X; Luo N; Wang X; Zheng X; Pan X
Toxicology; 2018 Dec; 410():231-246. PubMed ID: 30153467
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
